Garden Biotech: Subsidiary cholesterol production line will suspend production for maintenance for no more than 45 days

2026-03-04 17:03:45

Abstract generation in progress

Radar Finance | Written by Yang Yang | Edited by Li Yihui

On March 4th, Huayuan Biological (300401) announced that its wholly-owned subsidiary, Zhejiang Huayuan Nutrition Technology Co., Ltd., will shut down the cholesterol production line for maintenance according to the annual production and operation plan. The expected downtime will not exceed 45 days. During this period, aside from production activities, other business operations such as market development and customer engagement will continue normally.

The company stated that this temporary shutdown for maintenance is not expected to have a significant adverse impact on its operating performance.

Tianyancha data shows that Huayuan Biological was established on December 18, 2000, with a registered capital of 541.702388 million RMB. The legal representative is Shao Xujun, and its registered address is No. 2, Huayuan Kangping Road, Nanma Town, Dongyang City, Zhejiang Province. Its main business is the manufacturing of vitamins and pharmaceuticals.

Currently, the company’s chairman is Shao Xujun, the secretary is Yu Quanheng, with 1,021 employees, and the actual controller is Shao Qinxiang.

The company has stakes in 10 affiliated companies, including Zhejiang Huayuan Nutrition Technology Co., Ltd., Hangzhou Xiasha Biotechnology Co., Ltd., Hangzhou Luoshen Technology Co., Ltd., Hangzhou Pengmao Import and Export Co., Ltd., Zhejiang Huayuan Synthetic Biology Research Institute Co., Ltd., and others.

In terms of performance, the company’s revenue for 2022, 2023, and 2024 was 1.418 billion, 1.095 billion, and 1.243 billion RMB, respectively, with year-over-year growth of 26.89%, -22.78%, and 13.58%. Net profit attributable to shareholders was 384 million, 192 million, and 309 million RMB, with year-over-year changes of -20.68%, -49.87%, and 60.76%. During the same period, the company’s asset-liability ratio was 37.75%, 45.00%, and 42.66%.

Regarding risks, Tianyancha data shows the company has 38 internal Tianyan risks, 590 surrounding risks, 43 historical risks, and 193 warning alert risks.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.